AGM
SLNO

Alpine Global Management’s Soleno Therapeutics SLNO Stock Holding History

Alpine Global Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,824
Closed -$850K – 432
2024
Q2 		$850K Buy
+20,824
New +$882K 0.15% 121

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alpine Global Management's SLNO Position: Q3 2024 in Review

Alpine Global Management sold out of Soleno Therapeutics (SLNO) in Q3 2024, closing a stake of 20,824 shares — an estimated $850K sold.

Alpine Global Management first reported a position in SLNO in Q2 2024 and held it in 1 quarter. The position peaked at $850K in Q2 2024. 142 funds tracked by Wall St. Rank hold SLNO as of Q3 2024.

  • Alpine Global Management reported no remaining Soleno Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 20,824 Soleno Therapeutics shares in Q3 2024, an estimated $850K.
  • Alpine Global Management first reported a position in Soleno Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Soleno Therapeutics position peaked at $850K in Q2 2024.
  • 142 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.